# THC earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/THC) · [Earnings tab](https://www.lopjlb.com/stock/THC?tab=earnings) Updated: 2026-07-24T04:53:47 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarters, Tenet Healthcare (THC) has demonstrated consistent operational outperformance and strategic portfolio reshaping. Starting in Q2 2024, the company beat estimates driven by 21% USPI EBITDA growth and hospital margin expansion, raising FY24 EBITDA guidance by $300M and announcing a $1.5B buyback. By Q4 2024, full-year results showed 13% EBITDA growth, completion of 14 hospital sales ($5B proceeds), 70 ASC additions, and a 14% share count reduction, with 2025 guidance targeting 7% normalized EBITDA growth. Q1 2025 delivered 14% EBITDA growth and 320bps margin expansion, though management flagged policy uncertainty. Q2 2025 saw another strong beat, prompting a $395M guidance increase to $4.4-4.54B, fueled by high acuity, favorable payer mix, and cost controls, alongside $1.1B in executed buybacks and a new $1.5B authorization. Q3 2025 added a further guidance lift to $4.47-4.57B with higher CapEx and FCF outlook, while introducing 2026 uncertainty around exchange subsidies and DPP. Full-year 2025 results posted 14% EBITDA growth and robust FCF; 2026 guidance embeds a $250M headwind from exchange subsidy expiration but targets 10% core EBITDA growth via structural cost efficiencies and USPI expansion. Q1 2026 beat again with $5.4B revenue, $1.16B adjusted EBITDA (21.6% margin), 6% USPI growth, and hospital expense discipline, reaffirming full-year guidance despite exchange enrollment and Medicaid headwinds, and deploying $125M for seven ASC acquisitions. ## Latest CallCard · Q1 Tenet Healthcare Q1 2026 beat expectations with $5.4B revenue, $1.16B adj EBITDA (21.6% margin), driven by USPI growth (+6% YoY) and hospital expense discipline; reaffirmed full-year guidance despite exchange enrollment headwinds and Medicaid uncertainty; deployed $125M for 7 ASC acquisitions (half **Guidance:** vague **Tone:** mgmt 0 · Q&A pressure 0 · divergence 0 ## Quarter one-liners - **2026 Q1:** Tenet Healthcare Q1 2026 beat expectations with $5.4B revenue, $1.16B adj EBITDA (21.6% margin), driven by USPI growth (+6% YoY) and hospital expense discipline; reaffirmed full-year guidance despite exchange enrollment headwinds and Medicaid uncertainty; deployed $125M for 7 ASC acquisitions (half - **2025 Q4:** Tenet Healthcare reports strong 2025 results with 14% EBITDA growth, margin expansion, and robust free cash flow; 2026 guidance reflects $250M headwind from exchange subsidy expiration but targets 10% core EBITDA growth via structural cost efficiencies and USPI growth.','tone': {'mgmt': 0.3, 'mgmt_r - **2025 Q3:** THC Q3 beat with 12% EBITDA growth and margin expansion; raised FY25 EBITDA guidance to $4.47-4.57B, increased CapEx and FCF outlook; USPI and hospital segments strong; 2026 uncertainty on exchange subsidies and DPP.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emphasized strong execution, e - **2025 Q2:** Tenet Healthcare Q2 2025: strong outperformance across USPI and hospitals, raising full-year EBITDA guidance by $395M to $4.4-4.54B, driven by high acuity, payer mix, cost controls; deploying $1.1B in share buybacks, authorized $1.5B more.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlig - **2025 Q1:** THC Q1 2025 beats expectations with 14% EBITDA growth, 320bps margin expansion; reaffirms full-year guidance despite strong start, cites policy uncertainty but maintains growth strategy.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights strong fundamental outperformance across segments - **2024 Q4:** Tenet Healthcare delivered strong 2024 results with 13% EBITDA growth, portfolio transformation via 14 hospital sales ($5B proceeds), 70 ASC additions, and 14% share count reduction; 2025 guidance targets 7% normalized EBITDA growth, active share repurchases, and continued USPI expansion.','tone': { - **2024 Q3:** — - **2024 Q2:** THC Q2 beat driven by USPI 21% EBITDA growth and hospital margin expansion; raised FY24 EBITDA guidance $300M to $3.825-3.975B; new $1.5B buyback; debt paydown continues.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted Q2 results exceeding expectations, 12% consolidated EBITDA growt ## Theme arcs - **EBITDA growth** (improving): Consistent double-digit growth each quarter; guidance raised multiple times from $3.825-3.975B (FY24) to $4.47-4.57B (FY25) with 2026 core target of 10%. - **Margin expansion** (improving): Hospital margin expansion noted in Q2 2024; 320bps expansion in Q1 2025; continued margin expansion cited in Q3 2025, Q4 2025, and Q1 2026 (21.6% adj EBITDA margin). - **USPI growth** (improving): 21% EBITDA growth in Q2 2024; continued strong performance through 2025; +6% YoY in Q1 2026. - **Hospital performance** (improving): Margin expansion and expense discipline highlighted; high acuity and payer mix benefits in Q2 2025; expense discipline in Q1 2026. - **Capital allocation - share repurchases** (improving): New $1.5B buyback in Q2 2024; $1.1B deployed in Q2 2025 with additional $1.5B authorized; ongoing active repurchases. ## Guidance path 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/THC`